Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7254-7264

  Song, Kai ^a   Herzog, Brett H ^a   Sheng, Minjia ^a,d   Fu, Jianxin ^a,e   McDaniel, Michael ^a   Ruan, Jia ^c,e   Xia, Lijun ^a,b,e  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHANGIOGENESIS; MACROPHAGE MIGRATION INHIBITION; MALE; MANTLE CELL LYMPHOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; LYMPHANGIOGENESIS; LYMPHOMA, MANTLE-CELL; MALE; MICE; MICE, INBRED NOD; RANDOM ALLOCATION; THALIDOMIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891273505     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0750     Document Type: Article

References (46)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76.
2. Kadowaki I, Ichinohasama R, Harigae H, Ishizawa K, Okitsu Y, Kameoka J, et al. Accelerated lymphangiogenesis in malignant lymphoma: Possible role of VEGF-A and VEGF-C. Br J Haematol 2005;130:869-77.
3. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for newtargeted therapeutics. Nat Rev Cancer 2007;7:750-62.
4. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-9.
5. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012;13:716-23.
6. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 4952-7.
7. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-9.
8. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J Immunol 1999;163:380-6.
9. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90.
10. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011;35:380-6.
11. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45.
12. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibodydependent cellular cytotoxicity of rituximab-treated CD20 tumor cells. Clin Cancer Res 2008;14:4650-7.
13. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84:553-9.
14. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
15. Alitalo K. The lymphatic vasculature in disease. Nat Med 2011;17: 1371-80.
16. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56.
17. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005;115:2316-9.
18. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005; 115:2363-72.
19. Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res 2002;26:849-55.
20. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007;104: 11406-11.
21. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-SCID IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89.
22. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012;31:4499-508.
23. Schulz A, Durr C, Zenz T, Dohner H, Stilgenbauer S, Lichter P, et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood 2013;121:2503-11.
24. Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol 2001;2:141-8.
25. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
26. St Hill CA. Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci-Landmrk 2011;16:3233-51.
27. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010;140:460-76.
28. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 2009;4:e7067.
29. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-53.
30. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8: 618-31.
31. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
32. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers, shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
33. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159-69.
34. Ek S, Bjorck E, Hogerkorp CM, Nordenskjold M, Porwit-MacDonald A, Borrebaeck CA. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006;118:2092-7.
35. Mazur G, Jaskula E, Kryczek I, Dlubek D, Butrym A, Wrobel T, et al. Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol 2011;49:240-7.
36. Eyman D, Damodarasamy M, Plymate SR, Reed MJ. CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. J Cell Physiol 2009;220:376-81.
37. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer- Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. Br J Cancer 2006;95: 272-81.
38. Xu Y, Yuan L,MakJ, Pardanaud L, Caunt M, Kasman I, et al. Neuropilin- 2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 2010;188:115-30.
39. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008;13:331-42.
40. Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003;17:1914-5.
41. Kaufmann H, Raderer M, Wohrer S, Puspok A, Bankier A, Zielinski C, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-71.
42. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011;365:2241-2.
43. Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012;136:56-68.
44. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012;97: 416-22.
45. Cassella M, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci 2002;979:120-30.
46. Das S, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci 2008;1131:235-41.